Menu Back to Event-Details

European Regulatory Town Hall Meeting: EMA Relocation and Implication for Centralised Activities

Track:
DIAmond Sessions

Day & Time:
April 17, 11:00AM - 12:30PM (Central Europe Standard Time)

Session Number:
DMD1

Type:
Session

Title:
European Regulatory Town Hall Meeting: EMA Relocation and Implication for Centralised Activities

Chair(s):
Melanie Carr
Head of Stakeholders and Communication
European Medicines Agency (EMA), European Union, United Kingdom

Description:

The European Regulatory Town Hall will provide an opportunity to update on recent developments and future direction of the EMA, the European Commission and the EU regulatory network, with specific focus on the relocation of the EMA and the business continuity plans that are in place.

Come listen to the latest issues from a panel consisting of senior leadership from the EMA and National Competent Authorities.

  • Update on timelines for EMA’s relocation and next steps
  • Business continuity plans and measures being taken to address stakeholders needs
  • Spotlight on EMA’s priorities to 2020
  • Update from the European Commission on the state of play and next steps
  • Work ongoing to prepare for Brexit from CHMPs perspective
  • Response of the European Medicines Regulatory Network to prepare for Brexit
  • Stakeholders expectations for Brexit and beyond


Presentation(s) & Speaker(s):
Panel Discussion
Nicola Bedlington
Secretary General
European Patient's Forum, Belgium

Panel Discussion
Karl Broich, DrMed
President
Federal Institute for Drugs and Medical Devices (BfArM), Germany

Panel Discussion
Nathalie Moll
Director General
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium

Panel Discussion
Csilla Pozsgay
Director General
National Institute of Pharmacy and Nutrition, Hungary

Panel Discussion
Guido Rasi, MD
Executive Director
European Medicines Agency (EMA), European Union, United Kingdom

Panel Discussion
Andrzej Rys, MD
Director of Health Systems and Products
European Commission, European Union, Belgium

Panel Discussion
Tomas Salmonson, PhD
Chair CHMP; Senior Scientific Advisor
Medical Products Agency (MPA), Sweden